secwatch.observer — SEC 8-K summary
======================================

Issuer:     STANDARD BIOTOOLS INC. (LAB)
CIK:        0001162194
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0000950170-25-106636
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Standard BioTools Q2 revenue $21.8M, net loss improves; sells SomaLogic to Illumina for up to $425M
--------------------------------------------------------------------------------

- Q2 2025 continuing ops revenue $21.8M, down 3% YoY; net loss $17.7M vs $25.4M loss a year ago.
- Consumables revenue up 18% YoY to $10.5M; instruments down 26% to $5.2M; services down 8% to $6.1M.
- Adjusted EBITDA loss $16.1M vs $17.4M; targeting adjusted EBITDA breakeven in 2026.
- Announced sale of SomaLogic to Illumina for up to $425M cash plus royalties; expected close H1 2026.
- FY2025 revenue outlook: combined $165-175M; continuing ops $78-83M; cash $239.7M, expects ≥$550M post-close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1162194/000095017025106636/0000950170-25-106636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1162194/000095017025106636/lab-20250811.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-106636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer